

CITATION REPORT

List of articles citing

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

DOI: 10.1056/nejmoa1606038

New England Journal of Medicine, 2016, 375, 754-66.

Source: <https://exaly.com/paper-pdf/64487431/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1126	Neue Therapieoptionen für Patienten mit rezidiviertem Multiplem Myelom. 2016 , 3, 92-95		0
1125	Management of multiple myeloma first relapse after autologous hematopoietic stem cell transplantation. 2016 , 22, 395-405		
1124	Daratumumab and Blood-Compatibility Testing. <i>New England Journal of Medicine</i> , 2016 , 375, 2497	59.2	11
1123	Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. 2016 , 128, 2757-2764		56
1122	Sequencing of nontransplant treatments in multiple myeloma patients with active disease. 2016 , 2016, 495-503		6
1121	Haematological cancer: Improvements with daratumumab. 2016 , 13, 592		1
1120	Progress in Myeloma - A Monoclonal Breakthrough. <i>New England Journal of Medicine</i> , 2016 , 375, 1390-1392	59.2	33
1119	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016 , 375, 1319-1331	59.2	930
1118	Daratumumab in multiple myeloma: a guide to its use as monotherapy in the EU. 2016 , 32, 463-469		8
1117	Management of multiple myeloma in resource-constrained settings. 2016 , 43, 690-694		3
1116	A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival. 2016 , 43, 682-689		39
1115	Deferring autologous stem cell transplantation for consolidation of minimal residual disease in multiple myeloma. 2016 , 43, 709-711		3
1114	New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma. 2016 , 22, 5959-5965		29
1113	Daratumumab bei rezidiviertem oder refraktärem multiplem Myelom. 2016 , 19, 28-30		
1112	Lebensverlängerung statt Nihilismus. 2016 , 19, 204-205		
1111	Developments in the Field of Myeloma in the Last Decade. 2017 , 33, 3-7		2
1110	Proteasome inhibitors in cancer therapy. 2017 , 14, 417-433		437

1109	Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials. 2017 , 10, 207-215	15
1108	[Which recent results in Oncology and Hematology will have an impact on our practices? The point of view of Bulletin du Cancer editorial board]. 2017 , 104, 6-19	0
1107	Multiple myeloma in 2016: Fresh perspectives on treatment and moments of clarity. 2017 , 14, 73-74	7
1106	Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study. 2017 , 31, 997-1000	53
1105	Is immunotherapy here to stay in multiple myeloma?. 2017 , 102, 423-432	31
1104	Safety issues and management of toxicities associated with new treatments for multiple myeloma. 2017 , 10, 193-205	5
1103	Monoclonal antibody therapy in multiple myeloma. 2017 , 31, 1039-1047	45
1102	Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. 2017 , 281, 365-382	93
1101	Approvals in 2016: cost-benefit challenges of new anticancer agents. 2017 , 14, 133-134	3
1100	How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?. 2017 , 112, 153-170	27
1099	How I manage the toxicities of myeloma drugs. 2017 , 129, 2359-2367	28
1098	Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma. 2017 , 35, 1312-1319	84
1097	Immunotherapy for the treatment of multiple myeloma. 2017 , 111, 87-93	22
1096	Immunologic approaches for the treatment of multiple myeloma. 2017 , 55, 190-199	25
1095	Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party. 2017 , 102, e271-e274	7
1094	Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients. 2017 , 102, 970-976	18
1093	Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. 2017 , 23, 115-124	7
1092	The safety of daratumumab for the treatment of multiple myeloma. 2017 , 16, 753-760	4

1091	New Agents in Multiple Myeloma: An Examination of Safety Profiles. 2017 , 17, 391-407.e5	32
1090	How is patient care for multiple myeloma advancing?. 2017 , 10, 551-561	9
1089	Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab. 2017 , 129, 3386-3388	63
1088	Immunotherapy in hematologic malignancies: past, present, and future. 2017 , 10, 94	49
1087	CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy. 2017 , 99, 186-189	13
1086	A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. 2017 , 129, 3294-3303	125
1085	Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma. 2017 , 178, 196-208	13
1084	Daratumumab for the treatment of multiple myeloma. 2017 , 17, 887-893	23
1083	Novel investigational drugs active as single agents in multiple myeloma. 2017 , 26, 699-711	10
1082	Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2017 , 28, iv52-iv61	426
1081	Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma. 2017 , 17, 75-87	1
1080	Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma. 2017 , 98, 289-295	2
1079	Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. 2017 , 123, 3568-3575	8
1078	Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors. 2017 , 17, 471-478	23
1077	Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib. 2017 , 7, e570	24
1076	Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. 2017 , 130, 974-981	312
1075	Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients. 2017 , 403, 206-215	23
1074	Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions. 2017 , 179, 198-218	33

1073	Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma. 2017 , 18, 1061-1079	3
1072	The multi-faceted potential of CD38 antibody targeting in multiple myeloma. 2017 , 66, 697-703	14
1071	Which therapies will move to the front line for multiple myeloma?. 2017 , 10, 383-392	7
1070	Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. 2017 , 92, 578-598	88
1069	An update on the role of daratumumab in the treatment of multiple myeloma. 2017 , 8, 28-37	23
1068	Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016. 2017 , 17, 329-339	13
1067	Current Review on High-Risk Multiple Myeloma. 2017 , 12, 96-108	14
1066	Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. 2017 , 31, 1727-1734	35
1065	Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma. 2017 , 96, 2071-2078	2
1064	Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. 2017 , 6, e1386829	143
1063	Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. 2017 , 23, 7498-7511	98
1062	Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States. 2017 , 10, 1107-1119	14
1061	Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors. 2017 , 36, 585-598	7
1060	RETRACTED ARTICLE: Immuntherapie des multiplen Myeloms. 2017 , 20, 49-53	
1059	Severe refractory CIDP: a case series of 10 patients treated with bortezomib. 2017 , 264, 2010-2020	24
1058	Novel Immunotherapies for Multiple Myeloma. 2017 , 12, 344-357	27
1057	Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. 2017 , 18, 1327-1337	248
1056	Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. 2017 , 130, 2392-2400	182

1055	Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study. 2017 , 96, 1857-1866	12
1054	Management of Early Relapse, How to Navigate the Choices. 2017 , 17, S137-S139	
1053	Advances in immunotherapy in multiple myeloma. 2017 , 29, 460-466	12
1052	The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies. 2017 , 99, 449-458	5
1051	Renal insufficiency in patients with multiple myeloma. 2017 , 10, 151-158	
1050	Monoclonal Antibody Therapy for Multiple Myeloma: Progress and Clues for Response. 2017 , 17, S146-S148	
1049	Multiple myeloma. 2017 , 3, 17046	484
1048	Clinical trials evaluating potential therapies for light chain (AL) amyloidosis. 2017 , 5, 655-663	
1047	How I treat myeloma with new agents. 2017 , 130, 1507-1513	53
1046	Emerging therapies for multiple myeloma: Application in older adults. 2017 , 8, 413-416	0
1045	Immunotherapy in Multiple Myeloma. 2017 , 33, 292-298	1
1044	Immune signature profiling identified predictive and prognostic factors for esophageal squamous cell carcinoma. 2017 , 6, e1356147	40
1043	Activity of panobinostat in combination with bortezomib and dexamethasone in advanced, proteasome inhibitor refractory multiple myeloma. 2017 , 10, 159-163	1
1042	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. 2017 , 92, 1146-1155	22
1041	The proteasome and proteasome inhibitors in multiple myeloma. 2017 , 36, 561-584	150
1040	Diagnostik und Therapie des Multiplen Myeloms. 2017 , 20, 44-52	
1039	Urothelial cancer proteomics provides both prognostic and functional information. 2017 , 7, 15819	12
1038	Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma. 2017 , 77, 2013-2024	21

1037	[Multiple myeloma : What has been confirmed in therapy?]. 2017 , 58, 1250-1257	2
1036	Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study. 2017 , 106, 541-551	11
1035	Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach. 2017 , 17, 621-630	4
1034	The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma. 2017 , 8, 209-220	12
1033	How I treat first relapse of myeloma. 2017 , 130, 963-973	49
1032	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. 2017 , 130, 1198-1204	46
1031	Myelom: PFS deutlich länger durch Zugabe von Daratumumab zu Bortezomib/Dexamethason. 2017 , 20, 24-24	
1030	Assessing treatment efficacy in the subset of responders in a randomized clinical trial. 2017 , 28, 1640-1647	2
1029	Milestones in myeloma. 2017 , 10, 13-17	
1028	Addition eines CD38-Antiköpers zur Therapie des multiplen Myeloms. 2017 , 20, 24-25	
1027	Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future. 2017 , 17, 545-554	17
1026	Direct targeting of cancer cells with antibodies: What can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias?. 2017 , 85, 6-19	8
1025	Safety of ixazomib for the treatment of multiple myeloma. 2017 , 16, 973-980	14
1024	Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma. 2017 , 101, 81-88	25
1023	Second primary malignancies in multiple myeloma: an overview and IMWG consensus. 2017 , 28, 228-245	66
1022	Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy. 2017 , 37, 129-143	21
1021	Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis. 2017 , 52, 41-47	11
1020	Immunotherapy Strategies Against Multiple Myeloma. 2017 , 16, 717-726	3

1019	Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. 2017,	6
1018	The use of DTT in the resolution of the interferences generated by daratumumab in the blood bank. 2017, 19, 127-130	
1017	Myelomtherapie: Was es bei der Antikörpergabe zu beachten gilt. 2017, 20, 18-20	
1016	Should minimal residual disease negativity be the end point of myeloma therapy?. 2017, 1, 522-525	3
1015	Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. 2017, 1, 2105-2114	103
1014	Management of multiple myeloma in the relapsed/refractory patient. 2017, 2017, 508-517	43
1013	Carfilzomib boosted combination therapy for relapsed multiple myeloma. 2017, 10, 895-907	13
1012	New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib. 2017, 8, 107-121	17
1011	Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation. 2017, 6,	21
1010	CIK Cells and HDAC Inhibitors in Multiple Myeloma. 2017, 18,	0
1009	Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs. 2017, 8, 1444	44
1008	Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era. 2017, 6, 20	14
1007	Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling. 2018, 10, e2018014	11
1006	Highlights from the 58th meeting of the American Society of Haematology, 1-6 December 2016, San Diego, USA. 2017, 11, 725	
1005	New developments in the treatment of multiple myeloma - clinical utility of daratumumab. 2017, 11, 31-43	4
1004	Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma. 2017, 6,	9
1003	Should minimal residual disease negativity be the end point of myeloma therapy?. 2017, 1, 517-521	8
1002	Hematologic Malignancies: Plasma Cell Disorders. 2017, 37, 561-568	5

1001	Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. 2017 , 1, 455-466	43
1000	CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience. 2018 , 14, 197-206	21
999	Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. 2018 , 32, 1567-1574	31
998	Proteasome inhibitors for the treatment of multiple myeloma. 2018 , 19, 375-386	21
997	Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis. 2018 , 40, 480-494.e23	18
996	Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival. 2018 , 101, 237	54
995	Resistance to proteasome inhibitors and other targeted therapies in myeloma. 2018 , 182, 11-28	49
994	Discovery, Development, and Mechanisms of Action of the Human CD38 Antibody Daratumumab. 2018 , 153-195	1
993	Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by -Expanded Autologous NK Cells. 2018 , 24, 4006-4017	62
992	Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma. 2018 , 109, 1552-1561	4
991	The start of a new wave: Developments in proteasome inhibition in multiple myeloma. 2018 , 101, 220	12
990	Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma. 2018 , 103, e277-e278	21
989	Panobinostat and Multiple Myeloma in 2018. 2018 , 23, 516-517	32
988	Multiple Myeloma. 2018 , 463-483	
987	Treatment of Relapsed/Refractory Patients with Multiple Myeloma. 2018 , 73-96	1
986	Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis. 2018 , 100, 494-501	50
985	Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States. 2018 , 18, 152-160	27
984	Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. 2018 , 59, 2305-2317	9

983	Current developments in immunotherapy in the treatment of multiple myeloma. 2018 , 124, 2075-2085	42
982	Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies. 2018 , 13, 114-124	16
981	Immunopathogenesis and immunotherapy of multiple myeloma. 2018 , 107, 278-285	38
980	EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma. 2018 , 23, 594-602	17
979	Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft. 2018 , 36, 436-444	10
978	Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. 2018 , 48, 210-220	22
977	The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe. 2018 , 11, 219-237	21
976	A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. 2018 , 121, 74-89	15
975	Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?. 2018 , 97, 387-400	13
974	Current Status of Immuno-Oncology in Hematologic Cancers. 2018 , 641-655	
973	Therapy sequencing strategies in multiple myeloma: who, what and why?. 2018 , 14, 95-99	4
972	Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. 2018 , 107, 460-467	9
971	Triplet vs. doublet drug regimens for managing multiple myeloma. 2018 , 19, 137-149	16
970	Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives. 2018 , 29, 741-758	26
969	Antibody-based delivery of tumor necrosis factor (L19-TNF α) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model. 2018 , 144, 499-507	13
968	The bone-marrow niche in MDS and MGUS: implications for AML and MM. 2018 , 15, 219-233	81
967	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. 2018 , 16, 11-20	86
966	Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. 2018 , 131, 741-745	37

965	Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study. 2018 , 8, 41	18
964	Chimeric antigen receptor-modified T cells: CD19 and the road beyond. 2018 , 131, 2621-2629	96
963	Current use of monoclonal antibodies in the treatment of multiple myeloma. 2018 , 181, 447-459	28
962	Immunomodulatory effects of CD38-targeting antibodies. 2018 , 199, 16-22	48
961	Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?. 2018 , 23, 511-515	4
960	Going the distance: Are we losing patients along the multiple myeloma treatment pathway?. 2018 , 126, 19-23	6
959	MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment. 2018 , 55, 44-50	22
958	Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy. 2018 , 11, 423-435	15
957	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). 2018 , 24 Suppl 2, S83-S94	63
956	Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?. 2018 , 35, 289-302	1
955	Emerging Therapeutics for Myasthenia Gravis. 2018 , 319-333	
954	Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. 2018 , 8, 26	68
953	A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System. 2018 , 181, 707-710	7
952	Overcoming multiple myeloma drug resistance in the era of cancer 'omics'. 2018 , 59, 542-561	24
951	74-Year-old female with new monoclonal protein on serum immunofixation electrophoresis. 2018 , 51, 97-100	2
950	Personalized Therapy for Multiple Myeloma. 2018 ,	1
949	Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. 2018 , 57, 529-538	18
948	Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma. 2018 , 18, 44-51	24

947	Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. 2018 , 32, 719-728		12
946	Managing multiple myeloma in elderly patients. 2018 , 59, 1300-1311		11
945	Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services. 2018 , 182, 936-939		5
944	Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. 2018 , 59, 1364-1374		6
943	A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple Myeloma. 2018 , 103, 67-76		8
942	Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials. 2018 , 32, 971-978		20
941	Model-Based Meta-Analysis for Multiple Myeloma: A Quantitative Drug-Independent Framework for Efficient Decisions in Oncology Drug Development. 2018 , 11, 218-225		8
940	Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients. 2018 , 34, 775-783		6
939	Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. 2018 , 78, 19-37		70
938	Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2018 , 378, 518-528	59.2	568
937	Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison. 2018 , 23, 279-287		8
936	Treatment of Patients in First or Second Relapse. 2018 , 77-102		
935	CD38 antibodies in multiple myeloma: back to the future. 2018 , 131, 13-29		209
934	Early Phase Cancer Immunotherapy. 2018 ,		1
933	Cellular Therapy. 2018 , 133-184		
932	Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. 2018 , 32, 252-262		171
931	Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study. 2018 , 100, 10-19		6
930	Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion. 2018 , 5, 270-284		2

929	Global Approaches in Myeloma: Critical Trials That May Change Practice. 2018 , 38, 656-661	2
928	Kidney Transplant in the Era of Modern Therapy for Multiple Myeloma. 2018 , 102, 1994-2001	10
927	Present and Future of Immunotherapy in the Management of Multiple Myeloma. 2018 , 14, 403-410	7
926	Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab. 2018 , 14, 414-422	19
925	Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside. 2018 , 38, 675-680	17
924	Treatment of Relapsed Myeloma in a Patient With Renal Insufficiency. 2018 , 36, 2012-2016	1
923	Therapie des multiplen Myeloms bei älteren Patienten. 2018 , 21, 35-43	
922	Infusion Reactions With Monoclonal Antibody Therapy in Myeloma: Learning From Experience. 2018 , 14, 425-426	3
921	Practical Considerations for Antibodies in Myeloma. 2018 , 38, 667-674	5
920	Monoclonal Antibodies for Myeloma: Make It Easy!. 2018 , 14, 423-424	
919	The Immunobiology of Kidney Cancer. 2018 , JCO2018792648	36
918	Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. 2018 , 36, 728-734	164
917	Promise of Immune Therapies in Multiple Myeloma. 2018 , 14, 411-413	6
916	Collaborative Physician-Pharmacist-Managed Multiple Myeloma Clinic Improves Guideline Adherence and Prevents Treatment Delays. 2018 , 14, e674-e682	13
915	Multiple Myeloma. 2018 , 47, 418-425	
914	Plasmablastic lymphoma: current perspectives. 2018 , 8, 63-70	37
913	Biological Mechanisms of Minimal Residual Disease and Systemic Cancer. 2018 ,	
912	Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity. 2018 , 1100, 141-159	6

911	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. 2018 , 8, 109	97
910	Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma. 2018 , 19,	20
909	The power of proteasome inhibition in multiple myeloma. 2018 , 15, 1033-1052	25
908	Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. 2018 , 124, 4342-4349	20
907	CD38 as an immunotherapeutic target in multiple myeloma. 2018 , 18, 1209-1221	19
906	A Low-Cost Flash Photographic System for Visualization of Droplets in Drop-on-Demand Inkjet. 2018 , 62, 60502-1-60502-9	1
905	Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update. 2018 , 19,	30
904	Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma. 2018 , 24, 711-712	1
903	Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies. 2018 , 9, 2616	29
902	Lymphocyte-Specific Chromatin Accessibility Pre-determines Glucocorticoid Resistance in Acute Lymphoblastic Leukemia. 2018 , 34, 906-921.e8	36
901	Daratumumab plus lenalidomide and dexamethasone lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. 2018 , 103, 2088-2096	133
900	Daratumumab plus bortezomib and dexamethasone bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. 2018 , 103, 2079-2087	167
899	Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. 2018 , 132, 2555-2563	37
898	Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma. 2018 , 18, 693-702	3
897	A novel dual-cytokine-antibody fusion protein for the treatment of CD38-positive malignancies. 2018 , 31, 173-179	6
896	CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. 2018 , 9, 2134	128
895	Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites. 2018 , 124, 4358-4365	3
894	Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. 2018 , 132, 2546-2554	90

893	[Daratumumab for multiple myeloma]. 2018 , 105, 985-991	
892	Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. 2018 , 5, e479-e492	22
891	The challenges of checkpoint inhibition in the treatment of multiple myeloma. 2018 , 334, 87-98	10
890	Therapeutic antibodies for multiple myeloma. 2018 , 48, 957-963	9
889	Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma. 2018 , 35, 1859-1872	14
888	Future in the Past: Wedd. as a Source of New Natural Compounds with Antiproliferative and Cytotoxic Activity on Multiple Myeloma Cells. 2018 , 19,	15
887	Prognostic factors for multiple myeloma in the era of novel therapies. 2018 , 11, 863-879	16
886	Triplet therapies - the new standard of care for multiple myeloma: how to manage common toxicities. 2018 , 11, 957-973	6
885	Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies. 2018 , 438, 17-23	80
884	Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma. 2018 , 17, 2610-2621	10
883	Ixazomib: a novel drug for multiple myeloma. 2018 , 11, 761-771	13
882	How Does Genetics and MRD Impact Treatment or Doesn't It?. 2018 , 18, S69-S72	
881	Drug resistance in multiple myeloma. 2018 , 70, 199-208	122
880	Choosing an appropriate salvage therapy for a patient with multiple myeloma. 2018 , 19, 1511-1516	1
879	Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis. 2018 , 10, 2817-2823	6
878	Biology and management of primary effusion lymphoma. 2018 , 132, 1879-1888	46
877	Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist. 2018 , 2018, 88-96	12
876	Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients. 2018 , 2018, 103-109	1

875	A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. 2018 , 108, 267-273	1
874	A look at treatment strategies for relapsed multiple myeloma. 2018 , 18, 735-750	1
873	Management of Multiple Myeloma. 2018 , 16, 624-627	9
872	Optimizing therapy in bortezomib-exposed patients with multiple myeloma. 2018 , 11, 463-469	1
871	Targeted Treatments for Hematological Cancers. 2018 , 259-312	
870	Cellular immunotherapy as a therapeutic approach in multiple myeloma. 2018 , 11, 525-536	5
869	Determining treatment intensity in elderly patients with multiple myeloma. 2018 , 18, 917-930	9
868	Multiple Liver Nodules Mimicking Metastatic Disease as Initial Presentation of Multiple Myeloma. 2018 , 2018, 7954816	4
867	How I treat the young patient with multiple myeloma. 2018 , 132, 1114-1124	28
866	Seeking Convergence and Cure with New Myeloma Therapies. 2018 , 4, 567-582	5
865	International Forum on typing and matching strategies in patients on anti-CD38 monoclonal therapy. 2018 , 113, e36	
864	Maintenance and continuous therapy for multiple myeloma. 2018 , 18, 751-764	9
863	Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients. 2018 , 183, 60-67	16
862	Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials. 2018 , 2018, 7646913	8
861	Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice. 2018 , 101, 556-565	8
860	Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. 2018 , 7, e1486948	24
859	CD38 Is Robustly Induced in Human Macrophages and Monocytes in Inflammatory Conditions. 2018 , 9, 1593	86
858	The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma. 2018 , 75, 55-66	2

857	Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets. 2017 , 8, 1936	29
856	Daratumumab for the Treatment of Multiple Myeloma. 2018 , 9, 1228	46
855	Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma. 2018 , 8, 139	25
854	CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma. 2018 , 26, 1906-1920	23
853	Inhibition of HIF1 β -Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy. 2018 , 19,	7
852	The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma. 2018 , 18, 66	14
851	Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma. 2018 , 40, 1122-1139	16
850	Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States. 2018 , 24, 29-38	23
849	Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma. 2018 , 21, 793-798	7
848	Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. 2018 , 93, 985	31
847	Therapie des rezidierten und refraktären multiplen Myeloms. 2018 , 24, 613-624	
846	Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma. 2018 , 7, 3	12
845	The safety of bortezomib for the treatment of multiple myeloma. 2018 , 17, 953-962	38
844	Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma. 2018 , 14, 3111-3121	8
843	Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain. 2018 , 14, 1744806918797042	17
842	Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. 2018 , 93, 981-1114	115
841	CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance. 2018 , 9, 1676	25
840	Bilateral Angle Closure Following the Infusion of a Monoclonal Antibody to Treat Relapsing Multiple Myeloma. 2018 , 27, e145-e147	7

839	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. 2018 , 18, 533-540	7
838	[Infusion of Daratumumab in Combination Therapies - Practical Information for The Outpatient Area]. 2018 , 143, 1201-1206	3
837	Interference of Therapeutic Monoclonal Antibodies With Routine Serum Protein Electrophoresis and Immunofixation in Patients With Myeloma: Frequency and Duration of Detection of Daratumumab and Elotuzumab. 2018 , 150, 121-129	18
836	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). 2018 , 32, 1697-1712	61
835	Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. 2018 , 5, e563-e598	62
834	Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma. 2018 , 18, e339-e343	10
833	Glucocorticoids in multiple myeloma: past, present, and future. 2019 , 98, 19-28	45
832	Daratumumab for the treatment of AL amyloidosis. 2019 , 60, 295-301	20
831	Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies. 2019 , 54, 17-25	4
830	Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib. 2019 , 58, 157-168	50
829	Daratumumab proves safe and highly effective in AL amyloidosis. 2019 , 185, 342-344	33
828	Infectious and immunological sequelae of daratumumab in multiple myeloma. 2019 , 185, 187-189	18
827	Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients. 2019 , 110, 559-565	11
826	Approach to the Adult Acute Lymphoblastic Leukemia Patient. 2019 , 8,	11
825	Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma. 2019 , 187, 447-458	6
824	Resistance Mechanisms to Novel Therapies in Myeloma. 2019 ,	1
823	A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. 2019 , 6, e521-e529	138
822	Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Therapies. 2019 ,	2

821	Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials. 2019 , 12, 665-684	4
820	The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis. 2019 , 20, 1065-1069	41
819	Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis. 2019 , 4, 438-448	20
818	Surrogate endpoints in randomised controlled trials: a reality check. 2019 , 394, 281-283	16
817	Updates on CAR T-cell therapy in B-cell malignancies. 2019 , 290, 39-59	36
816	Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective. 2019 , 12, 5813-5822	16
815	Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma. 2019 , 186, 807-819	6
814	Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma. 2019 , 10, 2040620719854171	7
813	Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network. 2019 , 8,	14
812	Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. 2019 , 134, 668-677	59
811	A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. 2019 , 94, E319-E322	0
810	Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial. 2019 , 98, 2805-2814	4
809	Analysis of the efficacy and safety of bortezomib for treating newly diagnosed multiple myeloma through different administration methods. 2019 , 11, 8295-8302	0
808	The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. 2019 , 345, 103964	14
807	The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma. 2019 , 19, 889-898	3
806	The molecular biology of multiple myeloma. 2019 , 121-130	
805	A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?. 2019 , 7, 1629-1636	2
804	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. 2019 , 394, 2096-2107	253

803	Multiple myeloma: an overview of management. 2019 , 13, 1178224219868235	17
802	Peripheral neuropathy following bortezomib therapy in multiple myeloma patients: association with cumulative dose, heparanase, and TNF- β . 2019 , 98, 2793-2803	8
801	Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations. 2019 , 34, 84-94	19
800	Aktuelle immuntherapeutische Ansätze beim multiplen Myelom. 2019 , 14, 412-422	
799	CAR-T-Zell-Therapie bei fortgeschrittenem multiplen Myelom. 2019 , 22, 34-35	
798	Bortezomib and other proteasome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment. 2019 , 24 Suppl 2, S52-S62	19
797	Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. 2019 , 94, 1244-1253	24
796	Relapsed refractory multiple myeloma: a comprehensive overview. 2019 , 33, 2343-2357	50
795	Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). 2019 , 9, 70	11
794	[Multiple myeloma: New criteria for diagnosis and treatment, strong therapeutic hopes]. 2019 , 48, 825-831	1
793	Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta-analysis. 2019 , 103, 542-551	5
792	Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. 2019 , 121, 751-757	9
791	General principles and escalation options of immunotherapy in autoantibody-associated disorders of the CNS. 2019 , 1, 32	3
790	Progression with clinical features is associated with worse subsequent survival in multiple myeloma. 2019 , 94, 439-445	5
789	Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?. 2019 , 14, 1-10	
788	Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?. 2019 , 14, 31-38	10
787	New Drugs in Multiple Myeloma. 2019 , 70, 521-547	22
786	Novel Agents in Multiple Myeloma. 2019 , 25, 45-53	11

785	Immunotherapy in myeloma: how far have we come?. 2019 , 10, 2040620718822660	34
784	[Some important breakthroughs in oncology and hematology in 2018: A selection by the editorial board of Bulletin du Cancer]. 2019 , 106, 12-23	0
783	The therapeutic role of natural killer cells in multiple myeloma. 2019 , 2, e49	1
782	Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. 2019 , 19, 560-569	10
781	Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma. 2019 , 15, 459-473	8
780	Full Issue PDF. 2019 , 4, I-CLXXXII	
779	Multiple Myeloma: What Do We Do About Immunodeficiency?. 2019 , 10, 1675-1684	6
778	Cost-effectiveness analysis on binary/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myeloma. 2019 , 60, 2951-2959	5
777	Novel targets for the treatment of relapsing multiple myeloma. 2019 , 12, 481-496	16
776	Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma. 2019 , 64, 349-355	13
775	Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. 2019 , 10, 1121	49
774	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2019 , 380, 2104-2115	59.2 435
773	Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. 2019 , 394, 29-38	383
772	Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?. 2019 , 19, 585-592.e1	0
771	Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. 2019 , 12, 59	61
770	High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. 2019 , 54, 2027-2038	8
769	Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study). 2019 , 60, 2143-2151	9
768	Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. 2019 , 134, 421-431	80

767	Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis. 2019 , 10, 2040620719839025	17
766	Prolonged severe neutropenia after the first daratumumab administration for multiple myeloma with baseline neutropenia. 2019 , 98, 2231-2232	3
765	Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. 2019 , 125, 2991-3000	47
764	CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy. 2019 , 10, 760	35
763	Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy. 2019 , 20,	57
762	Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma. 2019 , 14, 187-196	6
761	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. 2019 , 20, 781-794	150
760	The treatment of multiple myeloma in an era of precision medicine. 2019 , 4, 153-162	2
759	Examination of CD302 as a potential therapeutic target for acute myeloid leukemia. 2019 , 14, e0216368	2
758	Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells. 2019 , 8, 1599636	15
757	Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study. 2019 , 94, 794-802	8
756	Dose Selection for Multiple Myeloma in Modern Era. 2019 , 9, e400-e406	2
755	Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration. 2019 , 5, 887-892	43
754	Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?. 2019 , 2019, 2186494	2
753	Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational Study. 2019 , 41, 866-881.e7	5
752	Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis. 2019 , 19, e478-e488	10
751	Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later. 2019 , 19, 73-92	58
750	Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. 2019 , 9, 38	37

749	Utilization Patterns of Single Fraction Radiation Therapy for Multiple Myeloma. 2019 , 19, e238-e246	2
748	Proteasome Inhibitors as Sensitizing Agents for Cancer Chemotherapy. 2019 , 207-228	1
747	A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. 2019 , 134, 123-133	65
746	Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma. 2019 , 79, 447-454	14
745	Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. 2019 , 185, 492-502	31
744	Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma. 2019 , 21, 35	1
743	Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma. 2019 , 98, 1999-2001	6
742	Reprint of "Immunomodulatory effects of CD38-targeting antibodies". 2019 , 205, 71-77	9
741	A U.S. Cost Analysis of Triplet Regimens for Patients with Previously Treated Multiple Myeloma. 2019 , 25, 449-459	4
740	Non-covalent proteasome inhibitor PI-1840 induces apoptosis and autophagy in osteosarcoma cells. 2019 , 41, 2803-2817	4
739	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. 2019 , 33, 2266-2275	188
738	MAIA under the microscope - bringing trial design into focus. 2019 , 16, 339-340	8
737	The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era. 2019 , 4, 112-117	2
736	Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study. 2019 , 98, 1435-1440	21
735	Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses. 2019 , 60, 2295-2298	4
734	The therapeutic challenge of late antibody-mediated kidney allograft rejection. 2019 , 32, 775-788	42
733	Evaluation of the safety and efficacy of daratumumab outside of clinical trials. 2019 , 109, 665-672	11
732	Subcellular compartmentalization of NAD and its role in cancer: A sereneNAde of metabolic melodies. 2019 , 200, 27-41	30

731	NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma. 2019 , 20, 619-620	3
730	HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action. 2019 , 11,	25
729	Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. 2019 , 9, 41	62
728	Multiple Myeloma: Current Advances and Future Directions. 2019 , 19, 255-263	14
727	Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013. 2019 , 186, e41-e44	40
726	JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM). 2019 , 109, 509-538	11
725	Chemotherapy and Beyond: Infections in the Era of Old and New Treatments for Hematologic Malignancies. 2019 , 33, 289-309	16
724	Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. 2019 , 37, 1228-1263	104
723	Daratumumab in multiple myeloma. 2019 , 125, 2364-2382	58
722	Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018. 2019 , 19, e324-e336	10
721	Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. 2019 , 19, 332-344	13
720	Immunotherapy: the good, the bad, the ugly, and the really ugly. 2019 , 59, 437-440	4
719	Case report: Impact of BITE on CAR-T cell expansion. 2019 , 2, e50	4
718	Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. 2019 , 14, e0211927	55
717	Risk-Based Therapeutic Strategies. 2019 , 25, 54-58	2
716	Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma. 2019 , 133, 1572-1584	33
715	Management of cardiovascular risk in patients with multiple myeloma. 2019 , 9, 26	37
714	Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma. 2019 , 41, 477-493.e7	7

713	Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. 2019 , 19, 275-284	12
712	Efficacy and safety of autologous stem cell transplantation in patients aged \geq 65 years with multiple myeloma in the era of novel agents. 2019 , 54, 1595-1604	8
711	Insights on Multiple Myeloma Treatment Strategies. 2019 , 3, e163	23
710	Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies. 2019 , 1956, 157-197	5
709	Aryl hydrocarbon receptor (AHR) functions in NAD metabolism, myelopoiesis and obesity. 2019 , 163, 128-132	16
708	The pharmacologic management of multiple myeloma in older adults. 2019 , 20, 887-902	6
707	Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France. 2019 , 2019, 4625787	6
706	Treatment of Multiple Myeloma With Daratumumab in a Kidney Transplant Patient. 2021 , 28, e488-e491	1
705	CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study. 2019 , 3, 1815-1825	15
704	Epigenetic Landscape in Leukemia and Its Impact on Antileukemia Therapeutics. 2019 ,	1
703	Proteostasis In The Endoplasmic Reticulum: Road to Cure. 2019 , 11,	15
702	Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets. 2019 , 2019, 6084012	10
701	Gegen CD38 gerichtete Therapie beim multiplen Myelom. 2019 , 22, 42-43	
700	The Anti-CD38 Antibody Therapy in Multiple Myeloma. 2019 , 8,	15
699	Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma. 2019 , 11,	6
698	Updates from the 2019 American Society of Clinical Oncology and European Hematology Association annual meetings: a Canadian perspective on high-risk cytogenetics in multiple myeloma. 2019 , 26, e581-e594	2
697	Monoclonal antibody utilization characteristics in patients with multiple myeloma. 2019 , 30, 859-865	2
696	Novel Immunotherapeutic Agents for the Treatment of Multiple Myeloma. 2019 , 42, 317-329	6

695	[CD38 antibodies in multiple myeloma]. 2019 , 35, 1001-1004	0
694	Daratumumab in untreated newly diagnosed multiple myeloma. 2019 , 10, 2040620719894871	14
693	Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. 2019 , 19, 9-22	15
692	A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma. 2019 , 19, 29-34	41
691	[First-line treatment of multiple myeloma]. 2019 , 60, 23-33	0
690	The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma. 2019 , 25, e98-e107	16
689	In Reply: Network Meta-analyses Are Not About a Single Treatment But About Sets of Regimens. 2019 , 41, 188-190	
688	Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment. 2019 , 19, e9-e11	14
687	Disseminated Cryptococcosis in a Patient with Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone. 2019 , 58, 843-847	12
686	A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis. 2019 , 60, 151-162	5
685	Navigating the treatment landscape in multiple myeloma: which combinations to use and when?. 2019 , 98, 1-18	40
684	The impact of Daratumumab on transfusion service costs. 2019 , 59, 1252-1258	10
683	CD38-Driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma. 2019 , 79, 2285-2297	78
682	Immunotherapeutic Approaches in Cancer. 2019 , 19-44	4
681	High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. 2019 , 95, 279-289	77
680	Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy. 2019 , 145, 561-571	14
679	Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. 2019 , 109, 79-90	7
678	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. 2020 , 105, 468-477	27

677	Autologous stem cell transplant in older patients (age \geq 65) with newly diagnosed multiple myeloma: A systematic review and meta-analysis. 2020 , 11, 93-99	5
676	Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients. 2020 , 105, e37-e40	21
675	Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation. 2020 , 55, 419-430	5
674	Strategies to improve patient-reported outcome completion rates in longitudinal studies. 2020 , 29, 335-346	11
673	Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data. 2020 , 29, 69-79	9
672	Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. 2020 , 20, e30-e37	36
671	Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma. 2020 , 20, 8-17.e16	31
670	Artificial Kappa Light Chain Restriction of Marrow Hematogones: A Potential Diagnostic Pitfall in Minimal Residual Disease Assessment of Plasma Cell Myeloma Patients on Daratumumab. 2020 , 98, 68-74	6
669	Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. 2020 , 34, 180-195	23
668	Current Development of Monoclonal Antibodies in Cancer Therapy. 2020 , 214, 1-70	9
667	Treatment of relapsed multiple myeloma: Evidence-based recommendations. 2020 , 39, 100616	29
666	Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. 2020 , 20, 509-518	31
665	Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis. 2020 , 267, 317-323	27
664	Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials. 2020 , 61, 37-46	5
663	The CD38 natural killer cell line KHYG1 transiently expressing CD16 in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide. 2020 , 69, 421-434	12
662	Multiple Myeloma and Related Disorders. 2020 , 1884-1910.e7	2
661	Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials. 2020 , 38, 229-243	14
660	Limited treatment options in refractory multiple myeloma: promising therapeutic developments. 2020 , 20, 31-44	3

659	Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation.. 2020 , 1, 86-98	68
658	Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. 2020 , 61, 691-698	9
657	Checklist for clinical applicability of subgroup analysis. 2020 , 45, 530-538	7
656	High expression of chaperonin-containing TCP1 subunit 3 may induce dismal prognosis in multiple myeloma. 2020 , 20, 563-573	5
655	Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma. 2020 , 21, 29-41	9
654	Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design. 2020 , 16, 4347-4358	34
653	Quadruplets come of age for newly diagnosed multiple myeloma. 2020 , 395, 94-96	
652	Sequence matters: elotuzumab more effective if used before daratumumab. 2020 , 61, 507-509	
651	Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome. 2020 , 189, 67-71	20
650	Implications for the monitoring of patients with multiple myeloma undergoing treatment with the anti-CD38 monoclonal daratumumab. 2020 , 57, 178-181	1
649	Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. 2020 , 38, 784-792	94
648	Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma. 2020 , 99, 137-145	2
647	The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma. 2020 , 41, 100643	7
646	New generation drugs for treatment of multiple myeloma. 2020 , 25, 367-379	18
645	Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients. 2020 , 104, 190-197	8
644	Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor. 2020 , 186, 111906	6
643	Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma. 2019 , 12,	18
642	Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma. 2020 , 4, e380	2

641	Daratumumab-induced Choroidal Effusion: A Case Report and Review of the Literature. 2020 , 20, e994-e997	1
640	Immunotherapy in multiple myeloma: when, where, and for who?. 2020 , 32, 664-671	2
639	Multiple myeloma current treatment algorithms. 2020 , 10, 94	59
638	How I treat relapsed and/or refractory multiple myeloma. 2020 , 12, 8955	2
637	Dapsone-Induced Hemolytic Anemia in Multiple Myeloma: Case Report of Various Differential Diagnoses. 2020 , 20, e821-e825	1
636	Primary refractory multiple myeloma: a real-world experience with 85 cases. 2020 , 61, 2868-2875	3
635	An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma. 2020 , 13, 795-802	1
634	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. 2020 , 8,	13
633	Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma. 2020 , 9,	15
632	Modern Treatments and Future Directions for Relapsed/Refractory Multiple Myeloma Patients. 2020 , 20, 736-743	2
631	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. 2020 , 396, 186-197	151
630	Daratumumab and antineoplastic therapy versus antineoplastic therapy only for people with newly diagnosed multiple myeloma ineligible for transplant. 2020 ,	78
629	Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020. 2020 , 9,	3
628	Actors on the Scene: Immune Cells in the Myeloma Niche. 2020 , 10, 599098	21
627	Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF- κ B signal pathway. 2020 , 25, 424-432	0
626	Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview. 2020 , 12,	2
625	Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment. 2020 , 13,	2
624	[Recurrent Therapy of Multiple Myeloma - Individualized Concepts from The Arsenal of Diverse Options]. 2020 , 145, 820-827	0

623	Recent Advances in the Treatment of Patients with Multiple Myeloma. 2020 , 12,	7
622	Sequencing multiple myeloma therapies with and after antibody therapies. 2020 , 2020, 248-258	4
621	Daratumumab subcutaneous formulation for the treatment of multiple myeloma. 2020 , 20, 1253-1259	1
620	Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. 2020 , 4, 3295-3301	12
619	Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients. 2020 , 26, 2011-2017	6
618	CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions. 2020 , 10, 1243	34
617	Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study. 2020 , 25, 2151-2157	1
616	Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis. 2020 , 112, 650-657	1
615	Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review. 2020 , 13, 943-958	8
614	Successful management of hemodialysis-dependent refractory myeloma with modified daratumumab, bortezomib and dexamethasone regimen. 2020 , 112, 860-863	3
613	How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis). 2020 , 20, e826-e831	2
612	Bilateral Secondary Angle Closure During Daratumumab Infusion: A Case Report and Review of the Literature. 2020 , 29, e83-e86	5
611	Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany. 2020 , 21, 1351-1361	3
610	Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches. 2020 , 10, 607571	
609	Treatment of relapsed, refractory multiple myeloma: focus on new drugs. 2020 , 42, 2-3	
608	Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple Myeloma. 2021 , 11,	
607	Autologous stem cell transplantation following simultaneous liver and kidney transplantation in severe amyloid light chain amyloidosis associated with multiple myeloma: a case report. 2020 , 14, 201	2
606	Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab. 2020 , 4, 5194-5202	9

605	Immunotherapeutic and Targeted Approaches in Multiple Myeloma. 2020 , 9, 201-215	9
604	Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience. 2020 , 9,	3
603	Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. 2020 , 21, 1630-1642	110
602	Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients. 2020 , 12,	8
601	Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma. 2020 , 16, 2783-2798	8
600	Assessment of Hazard Ratios in Oncology Clinical Trials Terminated Early for Superiority: A Systematic Review. 2020 , 3, e208633	0
599	Proteasomal Inhibition Potentiates Latent HIV Reactivation. 2020 , 36, 800-807	2
598	Safety of ninety-minute daratumumab infusion. 2021 , 27, 1080-1085	7
597	Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma. 2020 , 9,	6
596	How I manage frontline transplant-ineligible multiple myeloma. 2020 , 12, 8956	2
595	Current developments in the combination therapy of relapsed/refractory multiple myeloma. 2020 , 20, 1021-1035	5
594	Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis. 2020 , 6, 1759-1765	34
593	Use of daratumumab in high risk multiple myeloma: A meta-analysis. 2020 , 1, 267-271	7
592	Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma. 2020 , 80, 1455-1464	6
591	Emerging immunotherapies in multiple myeloma. 2020 , 370, m3176	27
590	Immune-based therapies in the management of multiple myeloma. 2020 , 10, 84	18
589	Frontline Therapy for Fit MM Patients Should Include an Antibody. 2020 , 20 Suppl 1, S81-S83	
588	Inhibition of Multiple Myeloma Using 5-Aza-2'-Deoxycytidine and Bortezomib-Loaded Self-Assembling Nanoparticles. 2020 , 12, 6969-6976	1

587	Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice. 2020 , 10,	5
586	Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy. 2020 , 12, 7891-7903	10
585	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. 2020 , 13, 115	15
584	CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers. 2020 , 29, 1295-1308	8
583	Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies. 2020 , 12,	12
582	Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. 2021 , 35, 2043-2053	10
581	EBV-related lymphoma after long-term daratumumab treatment: a case report. 2020 , 10, 113	1
580	Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum. 2020 , 3, 781	4
579	Recommendations on the management of multiple myeloma in 2020. 2020 , 1-17	1
578	Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients. 2020 , 10, 570187	3
577	Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation - a retrospective analysis. 2021 , 43, 437-442	
576	WITHDRAWN: Cost-effectiveness analysis of daratumumab plus bortezomib, melphalan and prednisone for newly diagnosed multiple myeloma ineligible for stem cell transplantation. 2020 ,	
575	Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy. 2020 , 11, 575609	11
574	Daratumumab: a game changer in myeloma therapy. 2020 , 7, e426-e427	3
573	Emerging agents and regimens for multiple myeloma. 2020 , 13, 150	23
572	Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients. 2020 , 9,	2
571	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. 2020 , 396, 1563-1573	92
570	Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True. 2020 , 21,	5

569	Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. 2020 , 135, 1541-1547	63
568	Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT. 2020 , 26, 1559-1566	3
567	Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. 2020 , 10, 58	3
566	Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress. 2020 , 99, 1681-1699	4
565	Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. 2020 , 135, 1517-1530	39
564	Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy. 2020 , 16, 571-578	17
563	Updates in the Diagnosis and Management of AL Amyloidosis. 2020 , 15, 155-167	6
562	Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. 2020 , 34, 3286-3297	33
561	Multiple myeloma: Current and future management in the aging population. 2020 , 138, 8-13	4
560	Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma. 2020 , 20, e579-e589	3
559	Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study. 2020 , 112, 84-95	0
558	The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. 2020 , 213, 107579	32
557	New drugs in early development for treating multiple myeloma: all that glitters is not gold. 2020 , 29, 989-1004	3
556	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. 2020 , 136, 936-945	189
555	The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma. 2020 , 10, 676	2
554	Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy. 2020 , 60, 51-54	7
553	Immunotherapy in hematologic malignancies. 2020 , 27, S124-S131	7
552	ImmunoPET in Multiple Myeloma-What? So What? Now What?. 2020 , 12,	4

551	Development of CAR-T cell therapies for multiple myeloma. 2020 , 34, 2317-2332	36
550	The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment. 2020 , 140, 377-396	5
549	Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy. 2020 , 38, 2647-2657	11
548	Choline PET/CT in Multiple Myeloma. 2020 , 12,	3
547	Storage, Utilization, and Disposal of Hematopoietic Stem Cell Products in Patients with Multiple Myeloma. 2020 , 26, 1589-1596	3
546	Evolution of diagnostic workup and treatment for multiple myeloma 2013-2019. 2020 , 105, 434-448	
545	Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance. 2020 , 20, e752-e768	10
544	Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches. 2020 , 10, 860	16
543	Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. 2020 , 33,	32
542	Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma. 2020 , 11, 1128	17
541	BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma. 2020 , 12,	24
540	Network meta-analysis of first-line treatments in transplant-ineligible multiple myeloma patients. 2020 , 105, 56-65	7
539	CNV Radar: an improved method for somatic copy number alteration characterization in oncology. 2020 , 21, 98	4
538	Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. 2020 , 126, 2791-2801	2
537	Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. 2020 , 10, 35	10
536	Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses. 2020 , 13, 331-349	11
535	Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement. 2020 , 61, 1752-1755	5
534	Immunotherapy in Multiple Myeloma. 2020 , 9,	18

533	Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. 2020 , 95, 548-567	235
532	NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies. 2020 , 12,	7
531	Efficacy of Panobinostat for the Treatment of Multiple Myeloma. 2020 , 2020, 7131802	21
530	Proteomics-inspired precision medicine for treating and understanding multiple myeloma. 2020 , 5, 67-85	1
529	DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma. 2020 , 99, 1041-1048	6
528	Recent Advances in the Management of Acute Lymphoblastic Leukaemia. 2020 , 21, 23	7
527	Relapse after Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma: Survival Outcomes and Factors Influencing Them. 2020 , 26, 1288-1297	7
526	Multiples Myelom [dynamische Entwicklungen in Krankheitsverständnis und Therapie. 2020 , 26, 661-672	
525	Natural History and Prognostic Factors at First Relapse in Multiple Myeloma. 2020 , 12,	1
524	Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab. 2020 , 20, e777-e781	4
523	The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. 2020 , 136, 2334-2345	26
522	Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma. 2020 , 13, 1345-1354	1
521	Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?. 2020 , 9,	8
520	Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR. 2020 , 42, 251-262.e5	8
519	The safety of current and emerging therapies for multiple myeloma. 2020 , 19, 269-279	4
518	The role of ubiquitination in tumorigenesis and targeted drug discovery. 2020 , 5, 11	133
517	Harnessing immunotherapy for pediatric T-cell malignancies. 2020 , 16, 361-371	6
516	Multiple Myeloma in a Young Female Presenting with Neurological Symptoms. 2020 , 2020, 1375174	1

515	Heat shock proteins as a new, promising target of multiple myeloma therapy. 2020 , 13, 117-126	4
514	Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. 2020 , 37, 1464-1478	4
513	Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost. 2020 , 111, 512-518	4
512	Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients. 2020 , 20, e137-e143	6
511	Multiple Myeloma: Available Therapies and Causes of Drug Resistance. 2020 , 12,	62
510	Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. 2020 , 38, 353-362	6
509	The underreporting of phase III chemo-therapeutic clinical trial data of older patients with cancer: A systematic review. 2020 , 11, 369-379	12
508	A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma. 2020 , 61, 1211-1219	7
507	Current Treatment Strategies for Multiple Myeloma. 2020 , 16, 5-14	13
506	Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. 2020 , 9,	21
505	Monitoring minimal residual disease in the bone marrow using next generation sequencing. 2020 , 33, 101149	5
504	The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future!. 2020 , 33, 101150	4
503	Antibody therapies for multiple myeloma. 2020 , 20, 295-303	5
502	Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action. 2020 , 33, 101143	12
501	Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study. 2020 , 111, 692-701	6
500	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. 2020 , 9, 1703449	81
499	PHLPP Sensitizes Multiple Myeloma Cells to Bortezomib Through Regulating LAMP2. 2020 , 13, 401-411	2
498	Addition of low-dose decitabine to bortezomib and dexamethasone as second-line therapy in multiple myeloma. 2020 , 189, e258-e262	4

497	AL patients don't dare go without dara. 2020 , 135, 1509-1510	2
496	Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities. 2020 , 10, 636	12
495	NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias. 2020 , 9,	17
494	Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. 2020 , 7, e370-e380 ⁹⁸	98
493	Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. 2020 , 99, 1049-1061	12
492	A pharmacodynamic model of clinical synergy in multiple myeloma. 2020 , 54, 102716	9
491	Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma. 2020 , 23, 441-450	5
490	EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. 2020 , 5,	5
489	Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma. 2020 , 9,	13
488	Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy. 2020 , 9,	9
487	Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis. 2020 , 191, 673-681	2
486	Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression. 2020 , 4, 1628-1639	5
485	Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. 2020 , 4, 830-844	21
484	Daratumumab in dialysis-dependent multiple myeloma. 2020 , 55, 65-67	7
483	Molecular screening for an underlying myeloproliferative neoplasm in patients with stroke: who and how?. 2020 , 55, 67-68	
482	High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate. 2020 , 95, 900-905	15
481	Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol. 2020 , 20, 526-532.e1	8
480	Evolving Role of Daratumumab: From Backbencher to Frontline Agent. 2020 , 20, 572-587	9

479	Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. 2021 , 35, 201-214	29
478	Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. 2021 , 35, 189-200	25
477	Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). 2021 , 106, 1725-1732	16
476	Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. 2021 , 35, 573-584	33
475	Approaching the first relapse after autologous transplant in multiple myeloma. 2021 , 4,	
474	Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. 2021 , 61, 614-627	3
473	Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. 2021 , 192, 869-878	15
472	Salvage second transplantation in relapsed multiple myeloma. 2021 , 35, 1214-1217	11
471	Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. 2021 , 56, 9-19	7
470	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. 2021 , 35, 18-30	29
469	Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma. 2021 , 106, 1193-1197	10
468	A pharmacist's review of the treatment of systemic light chain amyloidosis. 2021 , 27, 187-198	1
467	Changes in treatment landscape of relapsed or refractory multiple myeloma and their association with mortality: Insights from German claims database. 2021 , 106, 148-157	1
466	Monoclonal antibodies as an addition to current myeloma therapy strategies. 2021 , 21, 33-43	4
465	A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. 2021 , 39, 41-50	7
464	Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma. 2021 , 2, 56-65	9
463	Autoimmune encephalitis: novel therapeutic targets at the preclinical level. 2021 , 25, 37-47	9
462	Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison. 2021 , 13, 143-154	4

461	Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021. 2021 , 193, 705-722	12
460	Comparison of CD38-Targeted β - Versus β Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model. 2021 , 62, 795-801	9
459	A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma. 2021 , 14, 31-45	5
458	Myeloma clinical outcomes following the first wave of COVID-19: results from the Thames Valley Cancer Alliance (UK). 2021 , 192, e136-e139	1
457	Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? - Literature review. 2021 , 43, 185-190	2
456	Efficacy and safety of weekly carfilzomib (70 mg/m), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. 2021 , 62, 358-367	7
455	A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting. 2021 , 27, 907-910	1
454	Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents. 2021 , 113, 207-213	1
453	RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma. 2021 , 35, 1803-1807	5
452	Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma. 2021 , 113, 112-121	
451	Outcomes of lenalidomide- or bortezomib-based regimens in older patients with plasma cell myeloma. 2021 , 96, 14-22	1
450	Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance. 2021 , 193, 113-118	5
449	Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results. 2021 , 147, 619-631	5
448	Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment. 2021 , 68, 105-122	11
447	The Role of Targeted Therapy in Multiple Myeloma. 2021 , 1-15	
446	Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis. 2021 , 10, 1859263	3
445	Elective Discontinuation of CDK4/6 Inhibitors in Patients with Metastatic Hormone Receptor-Positive, Her-2-Negative Breast Cancer: A Retrospective Single-Center Experience. 2021 , 44, 443-449	0
444	Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma. 2021 , 536, 26-31	1

443	Management of Primary Plasma Cell Leukemia Remains Challenging Even in the Era of Novel Agents. 2021 , 14, 2634853521999389	1
442	Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany. 2021 , 24, 114-122	2
441	Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis. 2021 , 100, 725-734	4
440	New Targeted Therapies for Multiple Myeloma Under Clinical Investigation. 2021 , 129-145	
439	Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. 2021 , 12, 2040620720987075	4
438	Treatment of Multiple Myeloma with Kidney Involvement. 2021 , 179-208	
437	Risk of infection associated with targeted therapies for solid organ and hematological malignancies. 2021 , 8, 2049936121989548	6
436	Daratumumab. 2021 , 61-71	
435	A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China. 2021 , 113, 422-429	2
434	Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study. 2021 , 12, 20406207211035272	2
433	Old and new generation proteasome inhibitors in multiple myeloma. 2020 , 62, 193-206	1
432	The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells. 2021 , 11, 2074	0
431	How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in Myeloma. 2021 , 3, 27-33	
430	Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities. 2020 , 10, 606368	7
429	Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer. 2021 , 17, 42	1
428	Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. 2021 , 53, 1547-1559	4
427	Multiple myeloma. 2021 , 397, 410-427	77
426	Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study. 2021 , 100, 1065-1077	2

425	Comparative Effectiveness Research for CAR-T Therapies in Multiple Myeloma: Appropriate Comparisons Require Careful Considerations of Data Sources and Patient Populations. 2021 , 41, 201-210	3
424	CAR T cells targeting options in the fight against multiple myeloma. 2021 , 63, 37-45	0
423	Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational Study. 2021 , 8, 187-195	1
422	Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia. 2021 , 9, 139-151	0
421	Successful recovery of a patient with multiple myeloma from severe coronavirus disease 2019 (COVID-19) pneumonia during the first chemotherapy cycle: A case report. 2021 , 21, 392	3
420	Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients. 2020 , 10, 575168	2
419	Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. 2021 , 193, 561-569	0
418	Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group. 2021 , 100, 1059-1063	4
417	Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects. 2021 , 8, 612696	3
416	Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments. 2020 , 10, 624661	11
415	The Modern Age of Monoclonal Antibodies: The Revolution of Daratumumab.	
414	Molecular dynamics of targeting CD38 in multiple myeloma. 2021 , 193, 581-591	6
413	Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates. 2021 , 2, 116-130	0
412	Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis. 2021 , 159, 103211	5
411	Antibody-Based Treatment Approaches in Multiple Myeloma. 2021 , 16, 183-191	4
410	Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review. 2021 , 21, e267-e271	0
409	Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma. 2021 , 17, 993-998	1
408	Management of acute kidney injury in symptomatic multiple myeloma. 2021 , 99, 570-580	11

407	Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits. 2021 , 32, 1163-1173	9
406	Recent advances in the diagnosis and management of amyloid cardiomyopathy. 2021 , 10, 31	2
405	Real-World Treatment Patterns and Outcomes Among Multiple Myeloma Patients with Asthma and COPD in the United States. 2021 , 9, 195-212	1
404	Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma. 2021 , 4, e213497	1
403	Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches. 2021 , 5, 1340-1343	2
402	MUK OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukemia. 2021 , 11, e216825	5
401	Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. 2021 , 127, 1816-1826	5
400	Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial. 2021 , 21, 154-161.e3	4
399	Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide. 2021 , 18, 401-417	15
398	When and How to Treat Relapsed Multiple Myeloma. 2021 , 41, 358-375	3
397	Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma. 2021 , 13,	10
396	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. 2021 , 22, e105-e118	32
395	High drug loading and pH-responsive nanomedicines driven by dynamic boronate covalent chemistry for potent cancer immunotherapy. 2021 , 14, 3913	3
394	Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma. 2021 , 12, 608685	3
393	Boosting Immunity against Multiple Myeloma. 2021 , 13,	4
392	Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2021 , 32, 309-322	69
391	Facts and Hopes in Multiple Myeloma Immunotherapy. 2021 , 27, 4468-4477	2
390	Novel Experimental Drugs for Treatment of Multiple Myeloma. 2021 , 13, 245-264	9

389	Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France - a cohort study using the French National Healthcare database (SNDS). 2021 , 100, 1825-1836	0
388	Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies-Current Research and Clinical Approaches. 2021 , 10,	8
387	A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma. 2021 , 14, 377-389	3
386	Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens. 2021 , 1	0
385	Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based regimens: a analysis of phase 3 clinical trials. 2021 , 62, 2219-2226	1
384	Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. 2021 , 39, 1119-1128	8
383	Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment. 2021 , 10,	3
382	Etiology and management of hypertension in patients with cancer. 2021 , 7, 14	9
381	Role and Modulation of NK Cells in Multiple Myeloma. 2021 , 2, 167-181	1
380	Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens. 2021 , 11, 643490	2
379	Targeted Therapies for Multiple Myeloma. 2021 , 11,	2
378	Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. 2021 , 39, 1139-1149	23
377	Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review. 2021 , 13,	7
376	Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. 2021 , 21, 923-941	
375	Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. 2021 , 104, 106576	10
374	Expression of activated integrin α in multiple myeloma patients. 2021 , 114, 3-7	3
373	Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. 2021 , 21, 355-360	0
372	Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. 2021 , 100, 2325-2337	4

371	Multiple myeloma triplet therapies: baseline characteristics and control groups - Authors' reply. 2021 , 397, 1621-1623	
370	Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients. 2021 , 13,	4
369	Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma. 2021 , 21, e470-e476	3
368	Multiple Myeloma: "If You Don't Stop to Look Around Once in a While You Could Miss It". 2021 , 27, 183-184	
367	Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma. 2021 , 29, 6973-6980	0
366	Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. 2021 , 35, 3526-3533	5
365	A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trial. 2021 , 194, 580-586	1
364	Healthcare resource utilisation and sickness absence in newly diagnosed multiple myeloma patients who did not undergo autologous stem cell transplantation: Trends in Sweden with the changing treatment landscape. 2021 , 107, 92-103	
363	Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens. 2021 , 61, 2054-2063	3
362	Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. 2021 , 194, 784-788	2
361	Bioactive Compounds from Herbal Medicine Targeting Multiple Myeloma. 2021 , 11, 4451	1
360	Strategies to Overcome High-Risk Multiple Myeloma. 2021 , 27, 201-204	
359	Overcoming Drug Interference in Transfusion Testing: A Spotlight on Daratumumab. 2021 , 12, 327-336	0
358	Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. 2021 , 21, 701-710	1
357	Daratumumab provides a survival benefit in relapsed and refractory Multiple Myeloma, independent of baseline clinical characteristics: A meta-analysis. 2021 , 9, e00797	1
356	Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization. 2021 , 12, 694763	4
355	Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial. 2021 , 7, 862-868	23
354	Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. 2021 , 17, 1987-2003	8

353	Ninety-Minute Daratumumab Infusions for Relapsed and Refractory Multiple Myeloma: Two Years of Italian Single-Center Observational Study. 2021 , 21, e850-e852	1
352	US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma. 2021 , 13, 493-502	
351	Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. 2021 , 21, 785-798	2
350	Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma. 2021 , 13,	3
349	Role of Daratumumab in Combination With Standard Therapies in Patients With Relapsed and Refractory Multiple Myeloma. 2021 , 13, e15440	0
348	Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. 2021 , 1	1
347	Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety. 2021 , 15, 2401-2415	7
346	Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenarian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) - a new perspective. 2021 , 62, 3039-3042	2
345	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. 2021 , 22, 801-812	35
344	Flow cytometric myeloma measurable residual disease testing in the era of targeted therapies. 2021 , 43 Suppl 1, 71-77	
343	Successful treatment by glecaprevir/pibrentasvir followed by hepatoprotective therapy of acute chronic hepatitis exacerbation caused by daratumumab-based regimen for multiple myeloma: Case report and review of the literature. 2021 , 27, 1750-1755	2
342	Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population. 2021 , 21, 476-482	1
341	Cross fire: Daratumumab-based therapies are standard of care in newly diagnosed multiple myeloma. 2021 ,	
340	Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma. 2021 , 9,	1
339	Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data. 2021 , 46, 601-611	0
338	BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression. 2021 ,	6
337	Evolving Paradigms of Therapy for Multiple Myeloma: State of the Art and Future Directions. 2021 , 17, 415-418	0
336	Immunotherapy in Multiple Myeloma-Time for a Second Major Paradigm Shift. 2021 , 17, 405-413	5

335	Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data. 2021 ,	1
334	Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma. 2021 , 11, 703233	1
333	Selinexor for the treatment of patients with previously treated multiple myeloma. 2021 , 14, 697-706	3
332	A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma. 2021 , 21, 489-496	0
331	Antibody Therapies for Multiple Myeloma.	
330	Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence. 2021 , 112, 3645-3654	1
329	Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice. 2021 , 21, 470-475	4
328	Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia. 2021 , 14,	6
327	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA. 2021 ,	5
326	Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options. 2021 , 30, 965-973	4
325	Cyclophosphamide, Thalidomide, and Dexamethasone as Initial Therapy for Patients With Newly Diagnosed Multiple Myeloma in a Middle-Income Country: 7-Year Follow-Up. 2021 , 7, 1199-1205	0
324	Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). 2021 , 39, 3602-3612	14
323	NK cell surveillance of hematological malignancies. Therapeutic implications and regulation by chemokine receptors. 2021 , 80, 100968	1
322	Development of the Multiple Myeloma Symptom and Impact Questionnaire: A New Patient-Reported Outcome Instrument to Assess Symptom and Impacts in Patients With Multiple Myeloma. 2021 , 24, 1807-1819	1
321	Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma. 2021 , 8, 26-35	1
320	Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial. 2021 , 39, 1309-1325	1
319	Bispecific Antibodies in Multiple Myeloma: Present and Future. 2021 , 2, 423-433	8
318	Chemotherapy and peripheral neuropathy. 2021 , 42, 4109-4121	4

317	The evolving role and utility of off-label drug use in multiple myeloma.	
316	Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma. 2021 , 8, 26-35	
315	Isatuximab, a novel anti-CD38 monoclonal antibody in the treatment of multiple myeloma: efficacy and safety. 2021 , 23, 327-331	
314	Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study. 2021 , 39, 2758-2767	6
313	Treatment of double-refractory multiple myeloma. 2021 , 16, 58-73	2
312	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma. 2021 , 13,	2
311	Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma. 2021 , 13,	3
310	A 3D-Bioprinted Multiple Myeloma Model. 2021 , e2100884	2
309	Immunotherapy of Multiple Myeloma: Promise and Challenges. 2021 , 10, 343-371	1
308	The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies. 2021 ,	5
307	Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma. 2021 , 17, 4849-4860	2
306	The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma. 2021 , 13,	1
305	The high cost burden of third- to fifth-line treatments for multiple myeloma: unsustainable and unaffordable. 2021 , 27, 1321-1324	
304	Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials. 2021 , 21, 994	1
303	Infection in the CD38 and Anti-BCMA Era: Prevention and Treatment. 2021 , 21, S77	
302	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISM by clinical characteristics. 2022 , 108, 73-83	1
301	Prognostic and predictive biomarker developments in multiple myeloma. 2021 , 14, 151	4
300	The promise and perils of immunotherapy. 2021 , 5, 3709-3725	4

299	Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study. 2021 , 21, e699-e709	1
298	Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. 2021 , 22, 1378-1390	15
297	Recent therapeutic approaches in myeloma. 2022 , 1019-1029	
296	Immune Therapies for Hematologic Malignancies. 2021 , 13,	
295	Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy. 2021 , 38, 1328-1341	1
294	Epidemiology, Staging, and Management of Multiple Myeloma. 2021 , 9,	13
293	B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies. 2021 , 12, 2040620721989585	8
292	Neurological Complications. 2021 , 593-622	
291	A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. 2021 , 62, 1721-1729	0
290	New regimens and directions in the management of newly diagnosed multiple myeloma. 2021 , 96, 367-378	4
289	Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma. 2020 , 9, 2077-2084	14
288	Multiple Myeloma. 2020 , 61-95	1
287	Multiple Myeloma. 2018 , 277-284	4
286	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. 2020 , 7, e447-e455	32
285	Boron Quantum Dots for Photoacoustic Imaging-Guided Photothermal Therapy. 2021 , 13, 306-311	14
284	Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. 2020 , 34, 1875-1884	77
283	Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma. 2020 , 4, e350	13
282	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. 2021 , 5, e528	19

281	Exosomes mediate intercellular transfer of non-autonomous tolerance to proteasome inhibitors in mixed-lineage leukemia. 2020 , 111, 1279-1290	13
280	A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche. 2020 , 2020, 6820241	5
279	Immunotherapy of multiple myeloma. 2020 , 130, 1565-1575	42
278	Dominant-negative NFKBIA mutation promotes IL-1 β production causing hepatic disease with severe immunodeficiency. 2020 , 130, 5817-5832	3
277	Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. 2018 , 131, 855-863	83
276	Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. 2020 , 136, 71-80	86
275	Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. 2017 , 1, 2247-2256	11
274	Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function. 2020 , 4, 1321-1324	13
273	Renal, GI, and Peripheral Nerves: Evidence-Based Recommendations for the Management of Symptoms and Care for Patients With Multiple Myeloma. 2017 , 21, 19-36	5
272	How I treat elderly patients with plasma cell dyscrasias. 2018 , 10, 4248-4268	5
271	Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. 2017 , 8, 20394-20409	21
270	PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242. 2017 , 8, 39185-39197	11
269	Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma. 2017 , 8, 34001-34017	28
268	Emerging drugs and combinations to treat multiple myeloma. 2017 , 8, 60656-60672	28
267	T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. 2020 , 11, 4076-4081	10
266	Treatment of elderly patients with refractory/relapsed multiple myeloma: oral drugs adherence and the COVID-19 outbreak. 2020 , 11, 4371-4386	1
265	Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma. 2019 , 26, 5968-5981	5
264	Possible mechanisms of action of clarithromycin and its clinical application as a repurposing drug for treating multiple myeloma. 2020 , 14, 1088	4

263	Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells. 2020 , 13,	7
262	Why Immunotherapy Fails in Multiple Myeloma. 2021 , 2, 1-42	1
261	Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma. 2020 , 60, 17-20	3
260	Sudden Cardiac Arrest after Daratumumab Infusion. 2019 , 40, 301-303	3
259	Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/ Refractory Multiple Myeloma. 2020 , 41, 846-849	2
258	Treatment of relapsed and refractory multiple myeloma. 2020 , 55, S43-S53	9
257	Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population. 2019 , 163, 279-283	7
256	Scope of translational medicine in developing boron-containing compounds for therapeutics. 2017 , 6, 1	4
255	Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time. 2020 , 18, 278-285	5
254	The real-world outcomes of multiple myeloma patients treated with daratumumab. 2021 , 16, e0258487	3
253	AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: State-of-the-Art Review. 2021 , 3, 467-487	6
252	A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. 2021 , 14, 161	14
251	Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients. 2021 , 1-14	0
250	Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAiA): overall survival results from a randomised, open-label, phase 3 trial. 2021 , 22, 1582-1596	19
249	Clinical significance of SIRT3 and inflammatory factors in multiple myeloma patients with bortezomib-induced peripheral neuropathy: a cohort study. 2021 , 1-7	0
248	Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma. 2021 , 13,	1
247	Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/ β catenin signal pathway in prostate cancer cells. 2021 , 21, 1101	1
246	Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma. 2021 , 5, 5128-5139	3

245	Antibody incidence and red blood cell transfusions in patients on daratumumab. 2021 , 61, 3468-3472	1
244	Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update. 2021 ,	7
243	Advances in the Treatment of Relapsed and Refractory Multiple Myeloma in Patients with Renal Insufficiency: Novel Agents, Immunotherapies and Beyond. 2021 , 13,	4
242	Daratumumab: Dawn of a New Paradigm in Multiple Myeloma?. 2017 , 8, 82-90	1
241	Multiple Myeloma. 2017 ,	
240	Disease and Symptom Care: A Focus on Specific Needs of Patients With Multiple Myeloma. 2017 , 21, 3-6	1
239	Daratumumab. 2017 , 40, 240-241	
238	New Possibilities of Treatment for Relapsed/Refractory Multiple Myeloma: A Literature Review. 2017 , 10, 425-434	1
237	DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA. 2017 , 94-102	
236	Optimising Treatment in Relapsed, Refractory Multiple Myeloma. 2018 , 14, 96	
235	Biologie du mylome multiple : utilitclinique. 2018 , 202, 923-934	
234	CD38 targeted treatment for multiple myeloma. 2018 , 64, 939-948	3
233	Therapy for relapsed multiple myeloma. 2018 , 60, 174-184	1
232	Practical Aspects of the Use of Carfilzomib in Multiple Myeloma. 2018 , 12, 21-31	1
231	Genetic Segmentation and Targeted Therapeutics for Multiple Myeloma. 2019 , 15, 87	2
230	Moving Toward Continuous Therapy in Multiple Myeloma. 2019 , 1, 189-200	3
229	Myelomatous Pleural Effusion as a Presenting Symptom: A Case Report. 2019 , 11, e5153	1
228	Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.	

- 227 The late extramedullary relapse of the multiple myeloma with a predominant lesion of the duodenum and pancreas (clinical observation and mini-review). **2019**, 14, 27-39
- 226 AL Amyloidosis: Unfolding a Complex Disease. **2019**, 10, 813-825 0
- 225 Mylbme multiple. **2020**, 256-269.e4
- 224 Immunotherapeutic Strategies for Multiple Myeloma. **2020**, 75-102
- 223 Effect of bortezomib on proliferation and apoptosis of myeloma cells by activating Wnt/ β -catenin signaling pathway. **2020**, 20, 1295-1299 0
- 222 Recent Advances in the Treatment of Multiple Myeloma. **2020**, 109, 987-994
- 221 Isatuximab plus Pomalidomide and Dexamethasone in a Patient with Dialysis-Dependent Multiple Myeloma. **2021**, 66, 192-195 1
- 220 Daratumumab utilization and cost analysis among patients with multiple myeloma in a US community oncology setting. **2021**,
- 219 Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. **2021**, 1 1
- 218 Occurrence, Fate, Effects, and Risks of Dexamethasone: Ecological Implications Post-COVID-19. **2021**, 18, 0
- 217 Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis. **2021**, 1 1
- 216 Developments in immunosuppression. **2021**, 26, 91-96 4
- 215 Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy. **2021**, 13, e2021012 2
- 214 Daratumumab. **2020**, 41, 57-60
- 213 Essentials of the Immune Response and Immunophenotyping. **2020**, 1-14
- 212 Diagnosis and Treatment of Multiple Myeloma for Spinal Surgeons. **2020**, 34, 134-138
- 211 Adverse Cutaneous Reactions to Chemotherapeutic Agents. **2020**, 757-795
- 210 Cancer Immunotherapy Confers a Global Benefit. **2020**, 1-48

209	CD38: From Positive to Negative Expression after Daratumumab Treatment. 2020 , 12, e7627	2
208	Integrating Best Practices to Improve Outcomes in Relapsed/Refractory Multiple Myeloma. 2020 , 11, 306-311	0
207	Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials. 2021 , 11, 21916	0
206	Cardiovascular involvement in patients affected by multiple myeloma: a comprehensive review of recent advances. 2021 , 1-14	2
205	Herausforderungen in der Behandlung später antikörpermediierter Abstoßung. 2020 , 24, 302-308	
204	Emerging Monoclonal Antibodies for the Treatment of Multiple Myeloma.	0
203	The effect of novel therapies in high-molecular-risk multiple myeloma. 2017 , 15, 870-879	6
202	Integrating Emerging Data Into Clinical Practice: A Case-Based Approach for Multiple Myeloma. 2017 , 8, 365-377	2
201	Outcomes of Inpatient Administration of Restricted Antineoplastic Medications at a Large Academic Medical Institution. 2019 , 44, 481-496	
200	Understanding the roles of stress granule during chemotherapy for patients with malignant tumors. 2020 , 10, 2226-2241	3
199	Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. 2020 , 4, 5089-5092	4
198	[The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma]. 2021 , 42, 27-32	
197	Outcomes of kidney transplant recipients with ESKD due to plasma cell dyscrasia: A case series. 2021 , e14541	0
196	Current and prospective antibody-based therapies in multiple myeloma.. 2021 ,	0
195	Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM. 2021 , 13,	0
194	Nonselective proteasome inhibitors in multiple myeloma and future perspectives. 2021 , 1-13	1
193	Extramedullary relapse in a patient with multiple myeloma: a rare cause of gastrointestinal perforation and massive bleeding. 2021 , 14,	0
192	Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. 2021 , 1	1

191	Review: Effects of anti-CD38 monoclonal antibodies on red blood cell transfusion and interventions. 2021 , 35, e23832	1
190	Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study. 2021 , 21, 1207	1
189	Multiples Myelom. 2016 , 1-17	
188	Onkologika. 2021 , 579-638	
187	Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.. 2022 ,	3
186	High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.. 2022 , 41, 2	3
185	Current Treatment Approaches to Newly Diagnosed Multiple Myeloma. 2021 , 44, 690-699	3
184	Jahrestagung der American Society of Hematology: Neue Optionen bei Rezidiven.	
183	Management of Multiple Myeloma in Older Patients. 69-81	
182	Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group. 2022 , 3, 121-128	0
181	Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.. 2022 , 12, 9	4
180	Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT.. 2022 ,	1
179	Diverse Roles of F-BoxProtein3 in Regulation of Various Cellular Functions.. 2021 , 9, 802204	0
178	Cancer-cell-biomimetic Nanoparticles for Targeted Therapy of Multiple Myeloma Based on Bone Marrow Homing. 2021 , e2107883	5
177	Sequential Liver, Kidney, and Autologous Stem Cell Transplant for AL Amyloidosis: A Case Report.. 2021 , 54, 197-197	
176	Daratumumab: A review of current indications and future directions.. 2022 ,	0
175	The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies.. 2022 , 10, 1	1
174	How I Treat Relapsed Multiple Myeloma.. 2022 ,	2

173	Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance.. 2022 , 11,	1
172	Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry.. 2022 , 6, e683	0
171	Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021.. 2022 ,	0
170	Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone + subcutaneous daratumumab: patient-reported outcomes from the APOLLO trial.. 2022 ,	2
169	Diagnosis and Management of Multiple Myeloma: A Review.. 2022 , 327, 464-477	32
168	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.. 2022 , 9, e143-e161	6
167	Management of infectious risk of daratumumab therapy in multiple myeloma: a consensus-based position paper from an ad hoc Italian expert panel.. 2022 , 172, 103623	0
166	Practical Considerations for the Daratumumab Management in Portuguese Routine Clinical Practice: Recommendations From an Expert Panel of Hematologists.. 2021 , 11, 817762	
165	Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX, CASTOR and MAIA.. 2022 , 1-9	0
164	Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine.. 2022 , 12,	1
163	Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma. 2021 , 13,	4
162	Daratumumab for Immunoglobulin Light Chain Amyloidosis. 2021 , 17, 79	
161	A bibliometric analysis of CD38-targeting antibody therapy in multiple myeloma from 1985 to 2021.. 2022 , 11, 772-783	0
160	Drug resistance and minimal residual disease in multiple myeloma.. 2022 , 5, 171-183	0
159	Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies.. 2022 , 18, 1974-1988	0
158	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment.. 2022 , 13, 20406207221088458	
157	Re: Arcuri and Americo "Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis".. 2022 , 1	
156	Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain.. 2022 , 14, eaax7706	1

155	Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis.. 2022 , 12, 826342	0
154	Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma.. 2022 , 11,	0
153	Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis.. 2022 ,	
152	Belantamab mafodotin for relapsed or refractory multiple myeloma.. 2022 , 10781552221086265	
151	Carfilzomib 56 mg/m twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison.. 2022 , 1-10	
150	Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database.. 2022 , 29, 1575-1582	0
149	Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma.. 2022 , 12, 851864	0
148	Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis. 2022 ,	
147	Proteasome inhibition enhances myeloma oncolytic reovirus therapy by suppressing monocytic anti-viral immune responses.	
146	How I treat triple-class refractory multiple myeloma.. 2022 ,	1
145	Mesenchymal Stem Cells Inhibit the Effects of Dexamethasone in Multiple Myeloma Cells.. 2022 , 2022, 4855517	0
144	Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database.. 2022 ,	
143	Cardiovascular Complications of Modern Multiple Myeloma Therapy: Analysis of FDA Adverse Event Reporting System.	0
142	Tumor Microenvironment of Lymphomas and Plasma Cell Neoplasms: Broad Overview and Impact on Evaluation for Immune Based Therapies.. 2021 , 11, 719140	0
141	Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies.. 2021 , 7,	3
140	Anti-Interferon Autoantibodies in Adult-Onset Immunodeficiency Syndrome and Severe COVID-19 Infection.. 2021 , 12, 788368	0
139	Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma.. 2021 ,	2
138	Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile.. 2021 , 12,	10

137 Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations.. **2021**, 10600280211058754 2

136 Relapsed Plasmablastic Lymphoma in an HIV-Infected Patient Experience of High-Dose Chemotherapy with Autologous Stem Cell Rescue: A Case Report with Review of Literature.

135 Anti CD38 monoclonal antibodies for multiple myeloma treatment.. **2022**, 1-9 0

134 image_1.TIF. **2018**,

133 image_2.TIF. **2018**,

132 image_3.TIF. **2018**,

131 image_4.TIF. **2018**,

130 data_sheet_1.PDF. **2018**,

129 Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.. **2022**, 101, 1217

128 [Efficacy and safety of daratumumab in the treatment of advanced light chain amyloidosis].. **2022**, 43, 31-34

127 Incidence, causes, and timing of peripheral intravenous catheter failure related to insertion timing in the treatment cycle in patients with hematological malignancies: A prospective descriptive study.. **2022**, e12484 2

126 Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results. **2022**, 12, 0

125 The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches.. **2022**, 23, 1

124 A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022.. **2022**, 1-13 0

123 Multiple Myeloma: 2022 update on Diagnosis, Risk-stratification and Management.. **2022**, 12

122 Cancers of the Blood. **2022**, 67-131

121 Outcome of older Myeloma patients in relationship to comorbidities and availability of second-generation novel agents in a real-life setting.. **2022**,

120 Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese' .. **2022**,

- 119 How do we manage t(11;14) plasma cell disorders with venetoclax?. **2022**, 1
- 118 Effect modification in network meta-analyses of treatments for relapsing refractory multiple myeloma (RRMM): systematic review, meta-analysis, and simulation.
- 117 Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy. **2022**, 23, 5686 2
- 116 Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome. **2022**, 22,
- 115 Daratumumab triplet therapies in patients with relapsed or refractory Multiple Myeloma: a Real world experience. **2022**, 100330
- 114 Daratumumab+bortezomib+dexamethasone use in relapsed POEMS syndrome. 0
- 113 Pathogenesis and treatment of multiple myeloma. **2022**, 3, 0
- 112 Candidate therapeutic agents in a newly established triple wild-type mucosal melanoma cell line. 1
- 111 Real-world effectiveness and safety analysis of carfilzomib+lenalidomide+dexamethasone and carfilzomib+dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis. **2022**, 13, 204062072211045 0
- 110 Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth.
- 109 Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study. 1-10 2
- 108 Measurable Residual Disease Assessment in Multiple Myeloma: How Deep Is Enough?. **2022**, 3, 385-413
- 107 Bispecific T-cell engagers for treatment of multiple myeloma. 1
- 106 Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm. 12, 0
- 105 Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review. 0
- 104 On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: An early 2022 glance into the future. 0
- 103 Case Report: Invasive Fungal Infection and Daratumumab: A Case Series and Review of Literature. 12, 0
- 102 CyBorD-DARA in newly diagnosed transplant-eligible multiple myeloma: results from the 16-BCNI-001/TRIAL-IE 16-02 study show high rates of MRD negativity at end of treatment. **2022**, 1

101	Treatment Horizon in Multiple Myeloma.	0
100	Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma. 2022 , 39, 4230-4249	
99	Multiple Myeloma Therapy: Emerging Trends and Challenges. 2022 , 14, 4082	1
98	Pulmonary tuberculosis infection and CMV reactivation following daratumumab treatment in a patient with relapsed plasmablastic lymphoma. Publish Ahead of Print,	0
97	Choroidal effusion: a rare and unusual complication of daratumumab. 2022 , 15, e249735	
96	Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment. 2022 , 12, 1146	
95	Bispecific Antibodies for the Treatment of Multiple Myeloma.	
94	A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies. 2022 , 23, 8600	2
93	Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma. 2022 , 11, 4928	0
92	Cardiovascular Complications of Modern Multiple Myeloma Therapy: A Pharmacovigilance Study.	0
91	CD38 as a multifaceted immunotherapeutic target in CLL. 1-11	0
90	Efficacy and safety of cilta-cel in patients with progressive MM after exposure to other BCMA-targeting agents.	3
89	EXABS-123-MM Additional Agents for RRMM - How Do/Will They Fit. 2022 , 22, S24-S26	0
88	Multiple muscle involvement in relapsed multiple myeloma: A rare case. 2022 , 0	0
87	EGFR-Targeted Quinazoline Clubbed Heterocycles as Anticancer Agents. 2022 , 387-399	0
86	Combined targeting autophagy and metabolism for cancer therapy. 2022 , 215-238	0
85	Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.	0
84	Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.	0

83	Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies. 2022 , 12, 1261	0
82	Steps towards a Multiple Myeloma Cure?. 2022 , 12, 1451	1
81	RNA Therapeutics for Cancers.	0
80	Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma. 2022 , 6, e786	1
79	The Progress of Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma. 2022 , 12, 8963-8968	0
78	Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003).	0
77	Case report: Unexpected parvovirus B19 infection in a myeloma patient treated with daratumumab. 1,	0
76	Review of daratumumab efficacy in all monoclonal gammopathies and other diseases and our experience with daratumumab, lenalidomide and dexamethasone therapy in 74 patients. 2022 , 16, 61-82	0
75	Cumulative Incidence and Relative Risk of Infection in Multiple Myeloma Patients Treated with anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-Analysis.	0
74	High-cutoff hemodialysis in multiple myeloma patients with acute kidney injury. 12,	0
73	CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy. 13,	0
72	Plasma Cell Disorders. 1-30	0
71	Early intervention with a curative intent through an intensive therapy versus immunologic disease control using a minimal intensity approach in the management of high-risk smoldering multiple myeloma: A systematic review of evidence from clinical trials. 2022 ,	0
70	Magnetite Nanoparticles Coated with Biodegradable Zwitterionic Polymers as Multifunctional Nanocomposites for Drug Delivery and Cancer Treatment.	0
69	Additivity predicts the efficacy of most approved combination therapies for advanced cancer.	0
68	Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance. 12,	0
67	Monoclonal Antibody and Targeted Toxin Therapy. 1-31	0
66	Hotspots and trends in multiple myeloma bone diseases: A bibliometric visualization analysis. 13,	0

65	Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma. 13,	0
64	Multiple Myeloma. 2022 , 159-175	0
63	Rebooting the Myeloma Treatment Programme. 36-43	0
62	Real-world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel.	0
61	Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab.	0
60	Synergistically Anti-Multiple Myeloma Effects: Flavonoid, Non-Flavonoid Polyphenols, and Bortezomib. 2022 , 12, 1647	1
59	Isatuximab plus Carfilzomib and Dexamethasone vs Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation. 2022 ,	0
58	Patient Characteristics, Treatment Patterns and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data. 2022 ,	0
57	Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma. 2022 ,	0
56	Multiple Myeloma: Personalised Medicine Based on Pathogenesis. 78-89	0
55	CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4. 2022 , 89-112	0
54	Monocyte or white blood cell counts and \bar{M} microglobulin predict the durable efficacy of daratumumab with lenalidomide. 2022 , 13, 204062072211424	0
53	Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.	3
52	Management of Relapsed and Refractory Multiple Myeloma: Recent advances. 2022 , 43, 458-472	0
51	Savings associated with therapeutic appropriateness for patients with relapsed refractory multiple myeloma and high cytogenetic risk diagnosed by FISH test. 9, 105-111	0
50	Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer. 2022 , 10, 1993	0
49	Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment. 2022 , 29, 8975-9005	0
48	Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma. 2022 , 14, 6216	0

- 47 The first relapse in multiple myeloma: how to pick the next best thing. **2022**, 2022, 560-568 ○
- 46 Overcoming apoptotic resistance afforded by Bcl-2 in lymphoid tumor cells: a critical role for dexamethasone. **2022**, 8, ○
- 45 Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. **2022**, ○
- 44 Severe lung injury induced by CD38 monoclonal antibody Daratumumab and bortezomib-containing regimen in a patient with preexisting interstitial lung disease: a case report and literature review. **2022**, 47, 2387-2392 ○
- 43 The emerging therapeutic landscape of relapsed/refractory multiple myeloma. 1
- 42 Antibodies and bispecifics for multiple myeloma: effective effector therapy. **2022**, 2022, 163-172 ○
- 41 The impact of current therapeutic options on the health-related quality of life of patients with relapse/refractory multiple myeloma: a systematic review of clinical studies. ○
- 40 Combination of chemotherapeutic agents and biological response modifiers (immunotherapy) in triple-negative/Her2(+) breast cancer, multiple myeloma, and non-small-cell lung cancer. **2022**, 34, 1
- 39 How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma. **2023**, 15, 155 ○
- 38 Experts' consensus on the definition and management of high risk multiple myeloma. 12, 1
- 37 Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice. ○
- 36 An Effective Combination Therapy for the Treatment of Pediatric Monomorphic Post-transplant Lymphoproliferative Disorder With Plasmacytic Differentiation. Publish Ahead of Print, ○
- 35 Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies. ○
- 34 Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma. **2023**, ○
- 33 Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives. **2023**, 15, 963 ○
- 32 Immunotherapy for Multiple Myeloma. **2023**, 1-22 ○
- 31 Real-world evidence of daratumumab-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: A single-center experience in Taiwan focusing on efficacy. **2023**, 10, 19 ○
- 30 Increased Bone Volume by Ixazomib in Multiple Myeloma: 3-Month Results from an Open Label Phase 2 Study. ○

29	Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database. 2023 , 18, e0283931	0
28	Hämatologische Neoplasien und solide Tumore. 2022 , 85-151	0
27	Monoclonal gammopathy of renal significance: Multidisciplinary approach to diagnosis and treatment. 2023 , 183, 103926	0
26	Cytomegalovirus and Epstein-Barr virus infection during daratumumab treatment in patients with multiple myeloma. 2023 , 64, 835-845	0
25	Insuffisance rénale dans le myélome multiple : particularités de la prise en charge. 2023 ,	0
24	Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma.	1
23	Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. 2023 , 388, 1002-1014	1
22	Pomalidomide combinations are a safe and effective option after daratumumab failure.	0
21	Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. 2023 , 30, 2322-2347	0
20	CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD ⁺ -Lowering Agents. 2023 , 12, 494	0
19	A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study. 2023 , 28,	0
18	Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysis.	0
17	Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single-centre retrospective study.	0
16	Lessons for the clinical nephrologist: a rare case with MGRS characterized by combined crystalline light chain proximal tubulopathy and crystal-storing histiocytosis responding to daratumumab.	0
15	Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach. 2023 , 35, 149-160	0
14	Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.	0
13	Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma. 2023 , 23, 385-393	0
12	Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study. 2023 ,	0

- 11 Long-term storage protocol of reagent red blood cells treated with 0.01M dithiothreitol (DTT) for pre-transfusion testing of patients receiving anti-CD38 therapy, daratumumab. **2023**, 28, ○
- 10 Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. **2023**, 16, 415 ○
- 9 Daratumumab, Bortezomib, and Dexamethasone for Previously Treated Multiple Myeloma. ○
- 8 Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy. **2023**, 13, ○
- 7 Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). **2023**, 11, e006262 ○
- 6 A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed and Refractory Multiple Myeloma. **2023**, ○
- 5 Management of Relapsed/Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice. **2023**, 15, 2160 ○
- 4 Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy. **2023**, 15, 2240 ○
- 3 Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma. ○
- 2 Targeted therapy. **2023**, 205-411 ○
- 1 Targeted therapy. **2023**, 413-458 ○